Venous thromboembolism prevention resident survival guide: Difference between revisions
Jump to navigation
Jump to search
Rim Halaby (talk | contribs) |
Rim Halaby (talk | contribs) |
||
| Line 44: | Line 44: | ||
===Cancer in Outpatient=== | ===Cancer in Outpatient=== | ||
Shown below is an algorithm depicting VTE prophylaxis among cancer patients. Note that, | Shown below is an algorithm depicting VTE prophylaxis among cancer patients. Note that, cancer patients with indwelling central venous catheters do not require VTE prophylaxis with neither LMWH, low dose unfractionated heparin or vitamin K antagonists.<ref name="pmid22315261">{{cite journal| author=Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA et al.| title=Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. | journal=Chest | year= 2012 | volume= 141 | issue= 2 Suppl | pages= e195S-226S | pmid=22315261 | doi=10.1378/chest.11-2296 | pmc=PMC3278052 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22315261 }} </ref> | ||
{{Family tree/start}} | {{Family tree/start}} | ||
{{familytree | | | A01 | | | A01= Does the patient have a solid tumor <br> AND <br> | {{familytree | | | A01 | | | A01= ❑ Does the patient have a solid tumor <br> AND <br> ❑ Additional risk factors for VTE? | ||
:❑ Previous [[VTE]] | |||
:❑ Hormonal therapy | |||
:❑ Immobilization | |||
:❑ Angiogenesis inhibitors | |||
:❑ Thalidomide | |||
:❑ Lenalidomide}} | |||
{{familytree | |,|-|^|-|.| | }} | {{familytree | |,|-|^|-|.| | }} | ||
{{familytree | B01 | | B02 | | B01= Yes| B02= No}} | {{familytree | B01 | | B02 | | B01= Yes| B02= No}} | ||
Revision as of 13:51, 23 May 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]
Overview
VTE Prevention in Non Surgical Patients
Hospitalized Acutely Ill Medical Patients
Shown below is the indications and choices of VTE prophylaxis among acutely ill patients. If VTE prophylaxis is recommended, it should be administered for the period of immobilization or hospital stay. Do not extend the duration of the prophylaxis after the period of immobilization or hospital stay.[1]
| What is the risk of thrombosis in the acutely ill patient? | |||||||||||||||||||||||
| High | Low | ||||||||||||||||||||||
| Is the patient bleeding or at high risk of bleeding? | No VTE prophylaxis | ||||||||||||||||||||||
| Yes | No | ||||||||||||||||||||||
| Mechanical VTE prophylaxis For the period of immobilization or hospital stay only Graduated compression stocking Intermittent pneumatic compression | Pharmacological VTE prophylaxis For the period of immobilization or hospital stay only LMWH Low dose UFH, BID Low dose UFH, TID Fondaparinux | ||||||||||||||||||||||
| Did the bleeding or bleeding risk subside AND the patient is still at increased risk of thrombosis? | |||||||||||||||||||||||
| Yes | No | ||||||||||||||||||||||
| Substitute mechanical prophylaxis by pharmacological prophylaxis | Continue mechanical prophylaxis | ||||||||||||||||||||||
Critically Ill Hospitalized Patients
Shown below is an algorithm depicting the choices for VTE prophylaxis among critically ill patients. Note that routine ultrasound screening for DVT is not recommended among critically ill patients. Do not extend the duration of the prophylaxis after the period of immobilization or hospital stay.[1]
| Is the critically ill patient bleeding or at risk for major bleeding? | |||||||||||||||||
| Yes | No | ||||||||||||||||
| Mechanical VTE prophylaxis Graduated compression stocking Intermittent pneumatic compression | Pharmacological VTE prophylaxis LMWH Low dose UFH | ||||||||||||||||
| Did the bleeding or bleeding risk subside? | |||||||||||||||||
| Yes | No | ||||||||||||||||
| Substitute mechanical prophylaxis by pharmacological prophylaxis | Continue mechanical prophylaxis | ||||||||||||||||
Cancer in Outpatient
Shown below is an algorithm depicting VTE prophylaxis among cancer patients. Note that, cancer patients with indwelling central venous catheters do not require VTE prophylaxis with neither LMWH, low dose unfractionated heparin or vitamin K antagonists.[1]
| ❑ Does the patient have a solid tumor AND ❑ Additional risk factors for VTE?
| |||||||||||||||
| Yes | No | ||||||||||||||
| Pharmacological VTE prophylaxis LMWH Low dose UFH | No VTE prophylaxis | ||||||||||||||
Chronically Immobilized Patients
Long Travel
VTE Prevention in Non Orthopedic Patients
VTE Prevention in Orthopedic Patients
References
- ↑ 1.0 1.1 1.2 Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA; et al. (2012). "Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines". Chest. 141 (2 Suppl): e195S–226S. doi:10.1378/chest.11-2296. PMC 3278052. PMID 22315261.